Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not on Dialysis.

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: March 19, 2008
Last updated: October 28, 2013
Last verified: October 2013
This single arm study will assess the efficacy and safety of subcutaneous Mircera when administered for the maintenance of hemoglobin levels in patients with chronic renal anemia, not on dialysis. Patients currently receiving maintenance treatment with subcutaneous darbepoetin alfa or epoetin beta will receive monthly injections of Mircera, with the starting dose (120, 200 or 360 micrograms s.c.) derived from the dose of darbepoetin alfa or epoetin beta they were receiving in the week preceding study start. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

Condition Intervention Phase
Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Single Arm Open Label Study to Assess Efficacy, Safety and Tolerability of Once-monthly Administration of Subcutaneously Mircera for the Maintenance of Hemoglobin Levels in Patients With Chronic Renal Anemia Not on Dialysis

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Percentage of patients maintaining average Hb concentration within target range of 10.5-12.5g/dL during evaluation period. [ Time Frame: Weeks 17-24 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in Hb concentration, and percentage of patients maintaining Hb concentration in target range throughout evaluation period. [ Time Frame: Week 17-24 ] [ Designated as safety issue: No ]
  • Mean time in target range; percentage of patients needing dose adjustments; incidence of RBC transfusions. [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • AEs, laboratory parameters. [ Time Frame: Throughout study ] [ Designated as safety issue: No ]

Enrollment: 22
Study Start Date: March 2008
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
120, 200 or 360 micrograms sc monthly (starting dose)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adult patients, >=18 years of age;
  • chronic renal anemia;
  • stable darbepoetin alfa or epoetin beta therapy for past 8 weeks.

Exclusion Criteria:

  • transfusion of red blood cells during previous 8 weeks;
  • poorly controlled hypertension requiring interruption of epoetin treatment in previous 6 months;
  • acute or chronic bleeding requiring therapy within previous 8 weeks.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00642304

Almelo, Netherlands, 7609 PP
Amersfoort, Netherlands, 3818 ES
Amsterdam, Netherlands, 1034 CS
Assen, Netherlands, 9401 RK
Beverwijk, Netherlands, 1942LE
Breda, Netherlands, 4818 CK
Delft, Netherlands, 2625 AD
Doetinchem, Netherlands, 7009 BL
Dordrecht, Netherlands, 3318 AT
Drachten, Netherlands, 9202 NN
Goes, Netherlands, 4462 RA
Gouda, Netherlands, 2803 HH
Heerlen, Netherlands, 6419 PC
Hoogeveen, Netherlands, 7909
Leiden, Netherlands, 2333 ZA
Leiderdorp, Netherlands, 2353 GA
Maastricht, Netherlands, 6229 HX
Nijmegen, Netherlands, 6525 GA
Rotterdam, Netherlands, 3015 GD
Rotterdam, Netherlands, 3078 HT
Rotterdam, Netherlands, 3083 AN
Terneuzen, Netherlands, 4535 PA
Utrecht, Netherlands, 3582 KE
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche Identifier: NCT00642304     History of Changes
Other Study ID Numbers: ML20937 
Study First Received: March 19, 2008
Last Updated: October 28, 2013
Health Authority: Netherlands:Medicines Evaluation Board

Additional relevant MeSH terms:
Hematologic Diseases processed this record on October 26, 2016